Filing Flows › Profound Medical (PROF) › Q3 2026
Profound Medical (PROF) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Profound Medical (PROF) reported revenue of $9.8M for the third quarter 2026 (Q3 2026), +86% from a year earlier and +296% from the quarter before. Operating margin was -79.6%, net loss $7.7M (78.6% of revenue).
Profound Medical, Q3 2026: revenue $9.8M (+86% year over year), operating margin -79.6%, net loss $7.7M, operating cash flow −$5.0M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.8M | +296% | +86% |
| Operating profit | −$7.8M | — | — |
| Net earnings | −$7.7M | — | — |
| Operating cash flow | −$5.0M | — | — |
What changed
Revenue was $9.8M in Q3 2026, up 86% year over year and up 296% from the previous quarter. Capital equipment was the largest line at 58% of revenue. Capital equipment added $4.5M year over year (up 368%), 99% of the total change.
Gross margin was 78.1%, up 3.8 points from Q3 2025. Operating costs exceeded revenue by $7.8M, an operating margin of -79.6%. Operating expenses grew 21% against revenue growth of 86%. The fastest-growing cost line was SG&A (+31%). The quarter ended with a net loss of $7.7M, narrower than the previous quarter's $9.5M loss.
Operating cash flow was −$5.0M. Non-cash charges added back $133K of depreciation and amortization and $257K of share-based compensation. Working capital and other items added $2.3M.
Questions
What was Profound Medical's revenue in the third quarter 2026?
Profound Medical (PROF) reported revenue of $9.8M for the third quarter 2026 (Q3 2026), +86% from a year earlier and +296% from the quarter before.
Was Profound Medical profitable in the third quarter 2026?
Operating loss was $7.8M (-79.6% of revenue) and net loss $7.7M.
Source: Profound Medical 10-Q on SEC EDGAR.